tradingkey.logo

BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce® 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization Pathway

ReutersFeb 19, 2025 3:03 PM

- Recce Pharmaceuticals Ltd RCE.AX:

  • RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE II TRIAL OF RECCE® 327 GEL IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS, SUPPORTING ACCELERATED COMMERCIALIZATION PATHWAY

  • RECCE PHARMACEUTICALS LTD - R327G ACHIEVES 93% PRIMARY EFFICACY ENDPOINT IN 14 DAYS

  • RECCE PHARMACEUTICALS LTD - R327G SAFE AND WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

Source text: ID:nGNX6kyg2r

Further company coverage: RCE.AX

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI